Does the media prefer NAMS or ASND?

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Ascendis Pharma A/S's score of 1.01 indicating that NewAmsterdam Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BBIO or NAMS?

In the previous week, BridgeBio Pharma had 15 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 18 mentions for BridgeBio Pharma and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.29 beat BridgeBio Pharma's score of 0.70 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor AXSM or NAMS?

In the previous week, Axsome Therapeutics had 9 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 12 mentions for Axsome Therapeutics and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Axsome Therapeutics' score of 0.75 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SMMT or NAMS?

In the previous week, Summit Therapeutics and Summit Therapeutics both had 3 articles in the media. Summit Therapeutics' average media sentiment score of 1.67 beat NewAmsterdam Pharma's score of 1.29 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELAN or NAMS?

In the previous week, Elanco Animal Health had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 5 mentions for Elanco Animal Health and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Elanco Animal Health's score of 1.16 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NewAmsterdam Pharma (NAMS) Competitors

$33.28 -1.98 (-5.62%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$32.73 -0.55 (-1.65%)

As of 04:00 AM Eastern

Compare

NAMS vs. ASND, BBIO, AXSM, SMMT, and ELAN

Should you buy NewAmsterdam Pharma stock or one of its competitors? MarketBeat compares NewAmsterdam Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NewAmsterdam Pharma include Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Axsome Therapeutics (AXSM), Summit Therapeutics (SMMT), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry.

How does NewAmsterdam Pharma compare to Ascendis Pharma A/S?

NewAmsterdam Pharma (NASDAQ:NAMS) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

NewAmsterdam Pharma has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.37, suggesting that its share price is 63% less volatile than the broader market.

NewAmsterdam Pharma presently has a consensus target price of $49.00, suggesting a potential upside of 47.24%. Ascendis Pharma A/S has a consensus target price of $295.67, suggesting a potential upside of 11.48%. Given NewAmsterdam Pharma's higher probable upside, equities analysts clearly believe NewAmsterdam Pharma is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00

NewAmsterdam Pharma has higher earnings, but lower revenue than Ascendis Pharma A/S. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	172.91	-$203.82M	-$1.79	N/A
Ascendis Pharma A/S	$814.57M	20.31	-$258M	$8.67	30.59

In the previous week, Ascendis Pharma A/S had 4 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 7 mentions for Ascendis Pharma A/S and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Ascendis Pharma A/S's score of 1.01 indicating that NewAmsterdam Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to NewAmsterdam Pharma's net margin of -943.23%. Ascendis Pharma A/S's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
Ascendis Pharma A/S	57.87%	N/A	-8.37%

89.9% of NewAmsterdam Pharma shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Ascendis Pharma A/S beats NewAmsterdam Pharma on 12 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

BridgeBio Pharma (NASDAQ:BBIO) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

NewAmsterdam Pharma has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	32.41	-$724.93M	-$3.74	N/A
NewAmsterdam Pharma	$22.50M	172.91	-$203.82M	-$1.79	N/A

BridgeBio Pharma has a net margin of -124.42% compared to NewAmsterdam Pharma's net margin of -943.23%. BridgeBio Pharma's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

BridgeBio Pharma currently has a consensus target price of $94.63, suggesting a potential upside of 13.90%. NewAmsterdam Pharma has a consensus target price of $49.00, suggesting a potential upside of 47.24%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts clearly believe NewAmsterdam Pharma is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, BridgeBio Pharma had 15 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 18 mentions for BridgeBio Pharma and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.29 beat BridgeBio Pharma's score of 0.70 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

Summary

NewAmsterdam Pharma beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Axsome Therapeutics had 9 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 12 mentions for Axsome Therapeutics and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Axsome Therapeutics' score of 0.75 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

81.5% of Axsome Therapeutics shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Axsome Therapeutics has higher revenue and earnings than NewAmsterdam Pharma. Axsome Therapeutics is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.40	-$183.17M	-$3.73	N/A
NewAmsterdam Pharma	$22.50M	172.91	-$203.82M	-$1.79	N/A

Axsome Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

Axsome Therapeutics currently has a consensus target price of $259.05, suggesting a potential upside of 13.48%. NewAmsterdam Pharma has a consensus target price of $49.00, suggesting a potential upside of 47.24%. Given NewAmsterdam Pharma's higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Axsome Therapeutics has a net margin of -26.59% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-26.59%	-267.16%	-28.53%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Summary

Axsome Therapeutics and NewAmsterdam Pharma tied by winning 8 of the 16 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, Summit Therapeutics and Summit Therapeutics both had 3 articles in the media. Summit Therapeutics' average media sentiment score of 1.67 beat NewAmsterdam Pharma's score of 1.29 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

4.6% of Summit Therapeutics shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 83.5% of Summit Therapeutics shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summit Therapeutics has a beta of -1.26, indicating that its stock price is 226% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

Summit Therapeutics presently has a consensus target price of $26.97, indicating a potential upside of 76.29%. NewAmsterdam Pharma has a consensus target price of $49.00, indicating a potential upside of 47.24%. Given Summit Therapeutics' higher possible upside, research analysts clearly believe Summit Therapeutics is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.44
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

NewAmsterdam Pharma has higher revenue and earnings than Summit Therapeutics. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
NewAmsterdam Pharma	$22.50M	172.91	-$203.82M	-$1.79	N/A

Summit Therapeutics has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Summary

NewAmsterdam Pharma beats Summit Therapeutics on 8 of the 14 factors compared between the two stocks.

How does NewAmsterdam Pharma compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability.

Elanco Animal Health has a net margin of -4.95% compared to NewAmsterdam Pharma's net margin of -943.23%. Elanco Animal Health's return on equity of 7.42% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

In the previous week, Elanco Animal Health had 2 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 5 mentions for Elanco Animal Health and 3 mentions for NewAmsterdam Pharma. NewAmsterdam Pharma's average media sentiment score of 1.29 beat Elanco Animal Health's score of 1.16 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

97.5% of Elanco Animal Health shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 1.1% of Elanco Animal Health shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Elanco Animal Health has a beta of 1.68, indicating that its stock price is 68% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

Elanco Animal Health currently has a consensus price target of $28.55, indicating a potential upside of 13.61%. NewAmsterdam Pharma has a consensus price target of $49.00, indicating a potential upside of 47.24%. Given NewAmsterdam Pharma's stronger consensus rating and higher possible upside, analysts plainly believe NewAmsterdam Pharma is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

NewAmsterdam Pharma has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than NewAmsterdam Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.66	-$232M	-$0.50	N/A
NewAmsterdam Pharma	$22.50M	172.91	-$203.82M	-$1.79	N/A

Summary

Elanco Animal Health beats NewAmsterdam Pharma on 8 of the 15 factors compared between the two stocks.

Get NewAmsterdam Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NAMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NAMS vs. The Competition

Export

Metric	NewAmsterdam Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.12B	$3.05B	$7.05B	$12.61B
Dividend Yield	N/A	2.06%	2.68%	8.00%
P/E Ratio	-18.59	19.17	27.11	24.26
Price / Sales	172.91	838.79	587.92	117.88
Price / Cash	N/A	56.80	29.22	49.36
Price / Book	5.57	4.22	10.75	6.29
Net Income	-$203.82M	$64.26M	$3.58B	$330.66M
7 Day Performance	-10.03%	-3.58%	-2.06%	-1.32%
1 Month Performance	9.47%	2.12%	3.32%	-0.64%
1 Year Performance	50.11%	20.35%	26.36%	19.08%

NewAmsterdam Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NAMS NewAmsterdam Pharma	3.3754 of 5 stars	$33.28 -5.6%	$49.00 +47.2%	+54.5%	$4.12B	$22.50M	N/A	4	News Coverage
ASND Ascendis Pharma A/S	4.3715 of 5 stars	$266.97 -0.4%	$295.67 +10.7%	+51.6%	$16.65B	$814.57M	30.79	1,189	Positive News
BBIO BridgeBio Pharma	3.1076 of 5 stars	$77.91 +0.2%	$92.90 +19.2%	+78.8%	$15.26B	$502.08M	N/A	400	Analyst Forecast Insider Trade
AXSM Axsome Therapeutics	3.5238 of 5 stars	$249.76 +3.0%	$259.05 +3.7%	+109.5%	$12.85B	$638.50M	N/A	380
SMMT Summit Therapeutics	3.6734 of 5 stars	$15.88 -0.3%	$26.97 +69.9%	-38.8%	$12.33B	N/A	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NAMS) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. ASND, BBIO, AXSM, SMMT, and ELAN

How does NewAmsterdam Pharma compare to Ascendis Pharma A/S?

Summary

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

Summary

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Summary

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Summary

How does NewAmsterdam Pharma compare to Elanco Animal Health?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NewAmsterdam Pharma (NAMS) Competitors

NAMS vs. ASND, BBIO, AXSM, SMMT, and ELAN

How does NewAmsterdam Pharma compare to Ascendis Pharma A/S?

Which has more volatility and risk, NAMS or ASND?

Do analysts recommend NAMS or ASND?

Which has stronger earnings & valuation, NAMS or ASND?

Does the media prefer NAMS or ASND?

Is NAMS or ASND more profitable?

Do institutionals & insiders hold more shares of NAMS or ASND?

Summary

How does NewAmsterdam Pharma compare to BridgeBio Pharma?

Which has higher valuation and earnings, BBIO or NAMS?

Is BBIO or NAMS more profitable?

Do analysts recommend BBIO or NAMS?

Do insiders and institutionals have more ownership in BBIO or NAMS?

Does the media refer more to BBIO or NAMS?

Which has more risk and volatility, BBIO or NAMS?

Summary

How does NewAmsterdam Pharma compare to Axsome Therapeutics?

Does the media favor AXSM or NAMS?

Do institutionals and insiders hold more shares of AXSM or NAMS?

Which has preferable valuation & earnings, AXSM or NAMS?

Which has more volatility & risk, AXSM or NAMS?

Do analysts rate AXSM or NAMS?

Is AXSM or NAMS more profitable?

Summary

How does NewAmsterdam Pharma compare to Summit Therapeutics?

Does the media prefer SMMT or NAMS?

Do insiders and institutionals hold more shares of SMMT or NAMS?

Which has more risk & volatility, SMMT or NAMS?

Do analysts rate SMMT or NAMS?

Which has higher earnings and valuation, SMMT or NAMS?

Is SMMT or NAMS more profitable?

Summary

How does NewAmsterdam Pharma compare to Elanco Animal Health?

Is ELAN or NAMS more profitable?

Does the media prefer ELAN or NAMS?

Do insiders and institutionals believe in ELAN or NAMS?

Which has more risk and volatility, ELAN or NAMS?

Do analysts recommend ELAN or NAMS?

Which has higher valuation & earnings, ELAN or NAMS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NAMS vs. The Competition

NewAmsterdam Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools